EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis

Bin Gu, Min Li, Dan Li, Kaisen Huang iD

Journal of Cardiovascular Translational Research · 2025-04 · 18 (2) · 424-441

DOI: 10.1007/s12265-024-10587-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Translational Research, online erschienen am 13.01.2025. Verfasst von Bin Gu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Affiliated Hospital of Southwest Medical University, No.1 Section 1, Xiang Lin Road, Longmatan District, Luzhou, Sichuan, 6…. Hauptthemen laut MEDLINE: Proprotein Convertase 9, CRISPR-Cas Systems, Atherosclerosis, Gene Editing. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 139 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR-Cas9 gene editing technology, as an innovative biomedical tool, holds significant potential in the prevention and treatment of atherosclerosis. By precisely editing key genes such as PCSK9, CRISPR-Cas9 offers the possibility of long-term regulation of low-density lipoprotein cholesterol (LDL-C), which may reduce the risk of cardiovascular diseases. Early clinical studies of gene editing therapies like VERVE-101 have yielded encouraging results, highlighting both the feasibility and potential efficacy of this technology. However, clinical applications still face challenges such as off-target effects, immunogenicity, and long-term safety. Future research should focus on enhancing the specificity and efficiency of gene editing, optimizing delivery systems, and improving personalized treatment strategies. Additionally, the establishment of ethical and legal regulatory frameworks will be critical for the safe adoption of this technology. With the continued advancement of gene editing technology, CRISPR-Cas9 may become an important tool for treating atherosclerosis and other complex diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proprotein Convertase 9CRISPR-Cas SystemsAtherosclerosisGene EditingGenetic TherapyCholesterol, LDLHumansAnimalsBiomarkersGenetic Predisposition to DiseaseTreatment Outcome

Stichwörter der Autor:innen

AtherosclerosisCRISPR-Cas9Cardiovascular diseasesGene editingLDL-CPCSK9

Substanzen

Proprotein Convertase 9PCSK9 protein, humanBiomarkersCholesterol, LDL

Autor:innen und Institutionen

  • Department of Cardiology, Affiliated Hospital of Southwest Medical University, No.1 Section 1, Xiang Lin Road, Longmatan District, Luzhou, Sichuan, 646000, China.
  • Department of Cardiology, Neijiang Dongxing District People's Hospital, Neijiang, Sichuan, 641300, China.
  • Department of Cardiology, Affiliated Hospital of Southwest Medical University, No.1 Section 1, Xiang Lin Road, Longmatan District, Luzhou, Sichuan, 646000, China. huang_ks@outlook.com.

ORCID-Profile: Kaisen Huang

Zitieren

APA

Gu, B., Li, M., Li, D., & Huang, K. (2025). CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis. Journal of Cardiovascular Translational Research, 18(2), 424-441. https://doi.org/10.1007/s12265-024-10587-7

Vancouver

Gu B, Li M, Li D, Huang K. CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis. Journal of Cardiovascular Translational Research. 2025;18(2):424-441. doi:10.1007/s12265-024-10587-7

BibTeX
@article{Gu2025,
  author = {Gu, Bin and Li, Min and Li, Dan and Huang, Kaisen},
  title = {CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis},
  journal = {Journal of Cardiovascular Translational Research},
  year = {2025},
  volume = {18},
  number = {2},
  pages = {424--441},
  doi = {10.1007/s12265-024-10587-7}
}
Kostenlos starten →